PE20230821A1 - Anticuerpos anti-ccr8 para el tratamiento del cancer - Google Patents
Anticuerpos anti-ccr8 para el tratamiento del cancerInfo
- Publication number
- PE20230821A1 PE20230821A1 PE2022002058A PE2022002058A PE20230821A1 PE 20230821 A1 PE20230821 A1 PE 20230821A1 PE 2022002058 A PE2022002058 A PE 2022002058A PE 2022002058 A PE2022002058 A PE 2022002058A PE 20230821 A1 PE20230821 A1 PE 20230821A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- refers
- cancer
- ccr8
- monoclonal antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Referido a un anticuerpo monoclonal, o una porcion de union a antigeno del mismo, que se une especificamente al receptor de quimiocina 8 del motivo C-C (CCR8) expresado en la superficie de una celula, cuya secuencia se establece como SEQ ID NO: 1, y media en el agotamiento de la celula que expresa CCR8 por citotoxicidad celular dependiente de anticuerpos (ADCC). Tambien se refiere a un inmunoconjugado que comprende el citado anticuerpo monoclonal, en el que opcionalmente el agente citolitico es una citotoxina o un isotopo radiactivo; una molecula biespecifica que comprende el citado anticuerpo unida a un dominio de union que tiene una especificidad de union diferente; una composicion que comprende los citados anticuerpos monoclonal, inmunoconjugado o molecula biespecifica. Ademas, refiere a un acido nucleico aislado que codifica el citado anticuerpo monoclonal, un vector que comprende el citado acido nucleico y una celula huesped que comprende el citado vector. Dicho anticuerpo es util para el tratamiento del cancer para administrarlo como como monoterapia o en combinacion con un agente anticanceroso, tal como un inhibidor del punto de control inmune, por ejemplo, un anticuerpo anti-PD-1 o anti-PD-10 L1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993570P | 2020-03-23 | 2020-03-23 | |
| US202063041992P | 2020-06-21 | 2020-06-21 | |
| US202163157618P | 2021-03-05 | 2021-03-05 | |
| PCT/US2021/023430 WO2021194942A1 (en) | 2020-03-23 | 2021-03-22 | Anti-ccr8 antibodies for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230821A1 true PE20230821A1 (es) | 2023-05-19 |
Family
ID=75478295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002058A PE20230821A1 (es) | 2020-03-23 | 2021-03-22 | Anticuerpos anti-ccr8 para el tratamiento del cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230119066A1 (es) |
| EP (1) | EP4126950A1 (es) |
| JP (1) | JP2023519254A (es) |
| KR (1) | KR20220157446A (es) |
| CN (1) | CN115768792A (es) |
| AU (1) | AU2021244200A1 (es) |
| BR (1) | BR112022018636A2 (es) |
| CA (1) | CA3172697A1 (es) |
| CL (1) | CL2022002555A1 (es) |
| CO (1) | CO2022013599A2 (es) |
| IL (1) | IL296673A (es) |
| MX (1) | MX2022011701A (es) |
| PE (1) | PE20230821A1 (es) |
| TW (1) | TW202202521A (es) |
| WO (1) | WO2021194942A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| EP4010378A4 (en) | 2020-10-16 | 2023-07-26 | LaNova Medicines Limited | ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF |
| WO2022211046A1 (ja) | 2021-03-31 | 2022-10-06 | 塩野義製薬株式会社 | Ｃｃｒ８を抗原として認識するキメラ抗原受容体 |
| TW202313684A (zh) | 2021-06-04 | 2023-04-01 | 美商安進公司 | 抗ｃｃｒ８抗體及其用途 |
| TW202325732A (zh) * | 2021-06-25 | 2023-07-01 | 大陸商南京艾美斐生物醫藥科技有限公司 | 抗-ccr8抗体及其用途 |
| KR20240067052A (ko) | 2021-07-27 | 2024-05-16 | 애브비 인코포레이티드 | 항-ccr8 항체 |
| JP2024546169A (ja) * | 2021-12-23 | 2024-12-17 | コンセプト トゥー メディシン バイオテック カンパニー， リミテッド | 抗ｃｃｒ８抗体およびその使用 |
| TW202400648A (zh) * | 2022-04-29 | 2024-01-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｃｃｒ８抗體及其用途 |
| EP4532547A1 (en) | 2022-05-24 | 2025-04-09 | Bristol-Myers Squibb Company | Antibodies that bind to human ccr8 |
| EP4536278A2 (en) | 2022-06-07 | 2025-04-16 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| CN115058387B (zh) * | 2022-06-11 | 2023-12-01 | 重庆医科大学 | 一种人胚胎干细胞与前列腺癌细胞共培养制备抗前列腺癌药物的方法 |
| WO2024026400A2 (en) * | 2022-07-27 | 2024-02-01 | Varian Medical Systems, Inc. | Therapeutic combinations of titr effectors with radiation therapy |
| KR20250044359A (ko) * | 2022-08-04 | 2025-03-31 | 베이진 스위찰랜드 게엠베하 | 항-ccr8 항체 및 사용 방법 |
| WO2024040216A2 (en) * | 2022-08-19 | 2024-02-22 | Fibrogen, Inc. | Anti-ccr8 antibodies and uses thereof |
| AU2023336565A1 (en) | 2022-09-09 | 2025-02-20 | Bayer Aktiengesellschaft | Medical use of ccr8 antibodies and dosing schedule |
| WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062082A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062019A1 (en) | 2022-09-21 | 2024-03-28 | Synabs | Anti-ccr8 antibodies and uses thereof |
| WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| TW202421664A (zh) * | 2022-10-07 | 2024-06-01 | 美商建南德克公司 | 用抗ｃ—ｃ模體趨化因子受體８（ｃｃｒ８）抗體治療癌症之方法 |
| WO2024088346A1 (en) * | 2022-10-28 | 2024-05-02 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-ccr8 antibodies and uses thereof |
| CN118324910A (zh) * | 2023-01-10 | 2024-07-12 | 北京天诺健成医药科技有限公司 | Ccr8抗体的应用 |
| WO2024165470A1 (en) | 2023-02-06 | 2024-08-15 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors |
| WO2024255753A1 (zh) * | 2023-06-12 | 2024-12-19 | 南京蓬勃生物科技有限公司 | 结合人ccr8的抗体及其用途 |
| WO2025061993A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025061994A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| CN117186202B (zh) * | 2023-11-08 | 2024-02-02 | 北京大学第三医院（北京大学第三临床医学院） | 一种新细胞因子csbf及其在干眼治疗中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2275541B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP2360254A1 (en) | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
| US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| PT2177620E (pt) | 2003-03-05 | 2015-02-16 | Halozyme Inc | Glicoproteína hialuronidase solúvel (shasegp), processo para preparação da mesma, suas utilizações e composições farmacêuticas que a compreendem |
| RU2406760C3 (ru) | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007044756A2 (en) | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
| WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| CN108969763B (zh) | 2012-05-15 | 2023-11-14 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| CN107090041B (zh) | 2013-09-13 | 2018-11-16 | 百济神州有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SMT201900591T1 (it) | 2013-12-12 | 2019-11-13 | Jiangsu Hengrui Medicine Co | Anticorpo pd-1, frammento legante l'antigene dello stesso e applicazione medica dello stesso |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| EP3916017A1 (en) | 2014-12-22 | 2021-12-01 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| WO2016149201A2 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| US10696745B2 (en) | 2015-06-11 | 2020-06-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Anti-PD-L1 antibodies |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| IL257062B (en) | 2015-08-11 | 2022-07-01 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| KR102434314B1 (ko) | 2015-09-01 | 2022-08-19 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
| AU2016370376B2 (en) | 2015-12-14 | 2023-12-14 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| EP3402512A4 (en) | 2016-01-11 | 2019-09-25 | Armo Biosciences, Inc. | INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2018112032A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8 |
| PT3616720T (pt) * | 2017-03-29 | 2021-03-11 | Shionogi & Co | Composição medicinal para tratamento de cancro |
| WO2019157098A1 (en) | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
| CN110835374A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8×ctla-4双特异性抗体及其应用 |
| KR20210108996A (ko) | 2018-12-27 | 2021-09-03 | 시오노기세이야쿠가부시키가이샤 | 신규 항 ccr8 항체 |
-
2021
- 2021-03-22 MX MX2022011701A patent/MX2022011701A/es unknown
- 2021-03-22 BR BR112022018636A patent/BR112022018636A2/pt unknown
- 2021-03-22 TW TW110110284A patent/TW202202521A/zh unknown
- 2021-03-22 US US17/914,257 patent/US20230119066A1/en active Pending
- 2021-03-22 AU AU2021244200A patent/AU2021244200A1/en active Pending
- 2021-03-22 WO PCT/US2021/023430 patent/WO2021194942A1/en active Application Filing
- 2021-03-22 EP EP21718409.2A patent/EP4126950A1/en active Pending
- 2021-03-22 CN CN202180024063.9A patent/CN115768792A/zh active Pending
- 2021-03-22 KR KR1020227036358A patent/KR20220157446A/ko active Pending
- 2021-03-22 JP JP2022557776A patent/JP2023519254A/ja active Pending
- 2021-03-22 IL IL296673A patent/IL296673A/en unknown
- 2021-03-22 PE PE2022002058A patent/PE20230821A1/es unknown
- 2021-03-22 CA CA3172697A patent/CA3172697A1/en active Pending
-
2022
- 2022-09-20 CL CL2022002555A patent/CL2022002555A1/es unknown
- 2022-09-21 CO CONC2022/0013599A patent/CO2022013599A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022011701A (es) | 2022-10-07 |
| IL296673A (en) | 2022-11-01 |
| AU2021244200A1 (en) | 2022-11-24 |
| KR20220157446A (ko) | 2022-11-29 |
| TW202202521A (zh) | 2022-01-16 |
| CA3172697A1 (en) | 2021-09-30 |
| CO2022013599A2 (es) | 2022-10-11 |
| CN115768792A (zh) | 2023-03-07 |
| WO2021194942A1 (en) | 2021-09-30 |
| JP2023519254A (ja) | 2023-05-10 |
| BR112022018636A2 (pt) | 2023-01-31 |
| EP4126950A1 (en) | 2023-02-08 |
| US20230119066A1 (en) | 2023-04-20 |
| CL2022002555A1 (es) | 2023-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230821A1 (es) | Anticuerpos anti-ccr8 para el tratamiento del cancer | |
| MX2023004349A (es) | Anticuerpos monoclonales anti-ccr8 y sus usos. | |
| AR110676A1 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| MY205758A (en) | Anti-nkg2a antibodies and uses thereof | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| EA200970393A1 (ru) | Новые антитела к cd38 для лечения рака | |
| EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
| BR112018005573A2 (pt) | ?polipeptídeos de ligação a cd3? | |
| PE20241061A1 (es) | Polinucleotidos que codifican receptores de antigeno quimericos de flt3 | |
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| BRPI0717363B8 (pt) | imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina | |
| PE20091342A1 (es) | Inmunoglobulinas | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| CL2012001387A1 (es) | Anticuerpos murinos, humanizados o fragmentos de ellos anti-receptor epha2; conjugados citotoxicos; composiciones farmaceuticas que los contienen; secuencias nucleotidicas; vector; celula huesped e hibridomas que los producen y el uso de los anticuerpos en el tratamiento del cancer como en metodos de diagnostico. (divisional de sol. n° 2085-07) | |
| MX2017012278A (es) | Anticuerpos anti-ceacam6 y sus usos. | |
| AR080291A1 (es) | Anticuerpos antagonistas anti receptor de il-7 y procedimientos | |
| AR078470A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
| PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| UA98332C2 (ru) | Гуманизированное антитело к cd44, которое опосредует цитотоксичность в отношении раковых клеток | |
| WO2019138005A3 (en) | Novel combination and use of antibodies | |
| PE20230464A1 (es) | Union de anticuerpos multiespecificos a bcma | |
| AR064527A1 (es) | Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artiritis reumatoide |